Neurology:小脑性共济失调和帕金森病患者的冲动性特征

2022-05-27 Naomi MedSci原创

患有小脑性共济失调(CA)的人会出现冲动的行为症状。不同于帕金森患者,CA患者的冲动由非计划性特征驱动。这表明小脑和基底节可能以不同的方式控制冲动行为,小脑以一种特定领域的方式参与冲动的大脑回路。

患有小脑性共济失调(CA)的人会出现冲动的行为症状,通常会导致负面的人际关系后果,对他们的生活质量产生不利影响。关于CA的冲动及其相关的行为改变,目前存在的证据有限。近日,有研究人员使用Barratt冲动性来评估CA的冲动性特征采用抑郁自评量表(BIS-11),并与帕金森病(PD)患者进行比较,以探讨CA与PD在冲动特质方面的差异。

研究人员对分别来自哥伦比亚大学医学中心和范德比尔特大学医学中心的运动障碍门诊的CA和PD受试者进行了一项双中心横断面研究。在各自的机构招募了年龄匹配的对照组。如果参与者之前或同时患有已知与冲动有关的神经和精神疾病,则被排除在外。所有受试者都完成了BIS-11问卷,作为冲动特质的测量工具。使用一般线性模型和最小绝对收缩和选择操作回归来比较不同组间BIS-11的总分、分量表和单项得分。亚组分析是为了从小脑外病理和多巴胺能障碍或药物的潜在影响中分离出小脑对冲动的贡献。

  • 共有190名参与者:90名年龄匹配的对照组、50名CA和50名PD参与者完成了评估。
  • CA患者报告的BIS11得分比对照组高9.7%(p<0.001),而PD患者报告的BIS11得分比对照组高24.9%(p<0.001)。
  • 在CA中,受冲动影响最大的领域是非计划性。相反,帕金森病患者注意到在非计划领域、注意力领域和运动领域有更大的冲动。

与帕金森病患者不同,CA患者的冲动是由非计划性特征驱动的。这表明,小脑和基底节可能以不同的方式控制冲动行为,小脑以一种特定领域的方式参与冲动的大脑回路。

文献来源:Chen TX, Roy Lin CY, Aumann MA, et al. Impulsivity Trait Profiles in Patients With Cerebellar Ataxia and Parkinson Disease [published online ahead of print, 2022 Apr 15]. Neurology. 2022;10.1212/WNL.0000000000200349. doi:10.1212/WNL.0000000000200349

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2001821, encodeId=2dfb20018216e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Feb 28 17:48:46 CST 2023, time=2023-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757455, encodeId=5add1e5745535, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sat Sep 10 08:48:46 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011078, encodeId=606220110e82f, content=<a href='/topic/show?id=2ebe4e1478b' target=_blank style='color:#2F92EE;'>#小脑性共济失调#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47147, encryptionId=2ebe4e1478b, topicName=小脑性共济失调)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 28 11:48:46 CST 2023, time=2023-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573968, encodeId=166215e396811, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue May 24 07:48:46 CST 2022, time=2022-05-24, status=1, ipAttribution=)]
    2023-02-28 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=2001821, encodeId=2dfb20018216e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Feb 28 17:48:46 CST 2023, time=2023-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757455, encodeId=5add1e5745535, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sat Sep 10 08:48:46 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011078, encodeId=606220110e82f, content=<a href='/topic/show?id=2ebe4e1478b' target=_blank style='color:#2F92EE;'>#小脑性共济失调#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47147, encryptionId=2ebe4e1478b, topicName=小脑性共济失调)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 28 11:48:46 CST 2023, time=2023-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573968, encodeId=166215e396811, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue May 24 07:48:46 CST 2022, time=2022-05-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2001821, encodeId=2dfb20018216e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Feb 28 17:48:46 CST 2023, time=2023-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757455, encodeId=5add1e5745535, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sat Sep 10 08:48:46 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011078, encodeId=606220110e82f, content=<a href='/topic/show?id=2ebe4e1478b' target=_blank style='color:#2F92EE;'>#小脑性共济失调#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47147, encryptionId=2ebe4e1478b, topicName=小脑性共济失调)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 28 11:48:46 CST 2023, time=2023-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573968, encodeId=166215e396811, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue May 24 07:48:46 CST 2022, time=2022-05-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2001821, encodeId=2dfb20018216e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Feb 28 17:48:46 CST 2023, time=2023-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757455, encodeId=5add1e5745535, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sat Sep 10 08:48:46 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011078, encodeId=606220110e82f, content=<a href='/topic/show?id=2ebe4e1478b' target=_blank style='color:#2F92EE;'>#小脑性共济失调#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47147, encryptionId=2ebe4e1478b, topicName=小脑性共济失调)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 28 11:48:46 CST 2023, time=2023-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573968, encodeId=166215e396811, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue May 24 07:48:46 CST 2022, time=2022-05-24, status=1, ipAttribution=)]

相关资讯

JPD: 鉴别痴呆的脑脊液生物标记物,是否可用来鉴别帕金森病?

预测认知障碍的t-tau和p-tau的最佳临界值明显低于AD临界值,

JPD:神经丝轻链蛋白,或可预测帕金森的精神症状

精神病性症状与PD中更大的神经变性有关。

JPD:帕金森患者,视觉障碍,如何影响其生活质量

PD患者的视觉相关生活质量主要受视知觉、视觉建构能力和视觉注意力及处理速度改变的影响

JPD:苍白球内侧的神经变性,与步态冻结中多巴反应,关系密切

GPi的结构完整性作为FOG的多巴反应的相关因素

Neurology:帕金森病患者中运动和非运动症状与健康相关生活质量的关系

近日,研究人员发现潜在的可治疗的运动和非运动症状,特别是神经精神症状,是PwPD患者HRQOL变化的主要原因。这一发现为临床医生的干预和未来的症状管理研究提供了目标,以优化帕金森病患者的HRQOL。

JPD:下丘脑核团的结构连接改变,和冻结步态的息息相关

STN-DBS可以通过调节与前额叶和运动皮层结构相连的特定通路来减轻FOG的严重程度

拓展阅读

Nature子刊: 冲动性特征可以作为酒精问题和自杀遗传风险的早期指标

冲动性的特征可以作为酒精问题和自杀性的遗传风险的早期指标。

JCEM:多巴胺受体激动剂治疗的高泌乳素血症患者冲动控制障碍

由此可见,DA治疗具有较高的,以前被低估的ICD风险,尤其是在成年男性中以性欲亢进的形式表现出来。

Neurology:功能性磁共振显示帕金森合并冲动控制障碍时皮层纹状体连接存在障碍

帕金森除典型运动症状(静止性震颤、运动迟缓、肌强直和姿势步态异常)外,还伴有一些非运动症状,包括冲动控制障碍(impulse control disorders,ICD),帕金森患者中ICD患病率为5.9%-13.7 %。ICD是一组反复、过度的精神行为障碍。既包括对问题缺乏了解之前的贸然行动,缺乏思考的冒失反应,还包括难以抑制的对无关刺激或不当刺激的鲁莽行为。表现为无法控制的冲动和欲望,进而做出

CBMH:被监禁经历与物质滥用独立相关

  不断有研究指出心理疾病及物质滥用与刑事司法系统的介入有关,但对这种联系的调查主要集中在监狱服刑人员身上。通过与基于全国人口的心理障碍调查比较,推断心理障碍在此类人群中的超出率。   近期PubMed收载的一篇研究论文指出,在全部的评估指标中,仅发现物质滥用障碍与受监禁经历独立相关,考虑监狱调查的多样性后发现,物质滥用与其他严重的心理障碍相比存在此种相关性的概率更高。尽管研究没有涉及精